Toll-like receptor signaling pathways

**Toll-like receptor signaling pathways** refer to the intracellular cascades triggered by activation of Toll-like receptors (TLRs), which are pattern recognition receptors central to the innate immune system[1][2][4][5]. Upon recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), TLRs undergo dimerization and recruit adaptor proteins such as MyD88, TRIF, TIRAP/MAL, or TRAM[1][4][5]. These adaptors orchestrate downstream signaling resulting in the activation of key transcription factors including NF-κB, IRFs (interferon regulatory factors), and MAPKs, ultimately resulting in the induction of pro-inflammatory cytokines, chemokines, and type I interferons[1][2][4]. There are two principal arms of TLR signaling: the MyD88-dependent pathway (utilized by all TLRs except TLR3) that primarily induces inflammatory cytokines, and the TRIF-dependent pathway (activated by TLR3 and TLR4) that leads to production of type I interferons and late-phase inflammatory responses[1][2][4][5]. Dysregulation of these pathways is associated with a variety of diseases including infectious diseases, chronic inflammation, cancer, and autoimmunity[1][7]. **Note:** "Toll-like receptor signaling pathways" is not a single receptor or molecular target—rather, it refers to a group of cellular processes or a family of receptors and is thus not suitable as a canonical druggable target entity in a molecular database. The correct approach would be to refer to specific TLRs (e.g., "Toll-like receptor 4" or "Toll-like receptor 3") as actual targets[1][2][4].

Other names

TLR signaling pathwaysToll-like receptor pathwaysTLR cascades

Inhibition or activation of TLR receptors (agonism/antagonism) Blockade of ligand binding Inhibition of adaptor recruitment (e.g., MyD88, TRIF) Neutralization of downstream cytokines (e.g., anti-IL-6 therapies)